Deep Genomics, the AI-first TechBio company pioneering next-generation genomic medicines through its advanced AI foundation model platform, today announced the appointment of Thong Q. Le and Paul Sekhri to its Board of Directors. These appointments strengthen Deep Genomics’ leadership as it continues to leverage artificial intelligence to accelerate the discovery and development of transformative genetic therapies.
“We feel incredibly fortunate to welcome Thong and Paul to our Board of Directors,” said Brian O’Callaghan, Chief Executive Officer of Deep Genomics. “Their combined expertise in life sciences, biotechnology, and business strategy will be invaluable as we pursue our mission of delivering AI-powered genetic medicines to patients around the world.”
Thong Q. Le: Investment Expertise Meets Life Sciences Innovation
Thong Q. Le brings more than two decades of experience investing in and building life sciences companies. He currently serves as Investment Director and Managing Partner of the Strategic Investment Fund (SIF) at the Bill & Melinda Gates Foundation, where he has helped shape investment strategies that aim to improve global health outcomes. In addition, Mr. Le serves as Chairman of Accelerator Life Science Partners (ALSP), a venture capital firm dedicated to developing next-generation life science companies.
Throughout his career, Mr. Le has acted as founding president, CEO, or director for more than a dozen ALSP portfolio companies, including Petra Pharma, Rodeo Therapeutics, and Lodo Therapeutics. He also serves on multiple private biotech and nonprofit boards, applying his deep understanding of business development and strategic investment to foster innovation in the life sciences sector.
“In my time working in this industry, I’ve seen how the right combination of science, technology, and leadership can transform what’s possible in drug discovery,” said Mr. Le. “Deep Genomics embodies all of these elements, and I am excited to help guide its continued growth and impact on patient care.”
Paul Sekhri: Strategic Leadership Across Biotech and Pharma
Paul Sekhri brings more than 35 years of executive experience spanning biotechnology, pharmaceuticals, and life sciences. He currently serves as Chair, President, and CEO of vTv Therapeutics Inc., Chair of the Board of Resolution Therapeutics, and Executive Chair of Violet Therapeutics Inc. Previously, he held leadership roles as President and CEO of eGenesis Inc. and Lycera Corp., as well as senior management positions at Sanofi, Teva Pharmaceuticals, TPG Biotech, Cerimon Pharmaceuticals, Ariad Pharmaceuticals, and Novartis.
In addition to his corporate leadership roles, Mr. Sekhri serves on the boards of Veeva Systems, AdhereTech Inc., and Kayothera. He is also Chair of Young Concert Artists (YCA) and sits on the Advisory Council of the New York Philharmonic, reflecting a commitment to both innovation and community engagement.
“I am thrilled to join the Deep Genomics Board at such a pivotal moment for AI-driven therapeutics,” said Mr. Sekhri. “The company’s approach to advancing a new generation of medicines through AI is inspiring, and I look forward to contributing to its mission of transforming drug discovery and patient care.”
Driving AI-Powered Genomic Medicine
Deep Genomics has emerged as a leader in the rapidly evolving TechBio sector, combining artificial intelligence with genomics to identify novel drug targets, optimize therapeutic design, and accelerate clinical development. The company’s AI foundation model platform analyzes complex genetic data at scale, enabling researchers to predict the effects of genetic mutations and design precise interventions.
The appointments of Mr. Le and Mr. Sekhri further strengthen Deep Genomics’ governance and strategic oversight as the company scales its operations, expands its research initiatives, and continues to advance its portfolio of AI-driven genetic therapies. Their combined expertise in investment strategy, corporate leadership, and life sciences innovation provides the company with guidance critical for navigating the complexities of drug development and commercialization in the modern biotech landscape.
Brian O’Callaghan emphasized the significance of the new board members’ experience: “With Thong and Paul on board, Deep Genomics gains access to unparalleled insight into strategic growth, corporate governance, and biotech innovation. Their perspectives will help us continue to push the boundaries of what is possible in AI-enabled drug discovery.”
As Deep Genomics continues to bridge the gap between artificial intelligence and therapeutic development, the guidance and leadership of Thong Q. Le and Paul Sekhri are expected to accelerate the company’s mission: delivering transformative, AI-powered genetic medicines that can improve outcomes for patients worldwide.
